Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.